Amicus Therapeutics, Penn joins forces

Amicus Therapeutics entered into a joint venture with the Gene Therapy Program in the Perelman School of Medicine at the University of Pennsylvania to pursue research and development of novel gene therapies for Pompe disease, Fabry disease, CDKL5 deficiency and one additional undisclosed rare metabolic disorder.

Read More »